Form 8-K - Current report:
SEC Accession No. 0001193125-24-165656
Filing Date
2024-06-21
Accepted
2024-06-21 16:07:00
Documents
14
Period of Report
2024-06-20
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d783830d8k.htm   iXBRL 8-K 37282
2 EX-3.1 d783830dex31.htm EX-3.1 6913
  Complete submission text file 0001193125-24-165656.txt   174399

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aura-20240620.xsd EX-101.SCH 2835
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aura-20240620_lab.xml EX-101.LAB 18723
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aura-20240620_pre.xml EX-101.PRE 11694
17 EXTRACTED XBRL INSTANCE DOCUMENT d783830d8k_htm.xml XML 3831
Mailing Address 80 GUEST STREET BOSTON MA 01235
Business Address 80 GUEST STREET BOSTON MA 01235 (617)500-8864
Aura Biosciences, Inc. (Filer) CIK: 0001501796 (see all company filings)

EIN.: 320271970 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40971 | Film No.: 241060208
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)